Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide - PubMed
4 hours ago
- #radiographic progression
- #enzalutamide
- #prostate cancer
- Post hoc analysis of ARCHES and PROSPER trials evaluated radiographic progression (rPD) with and without PSA rise in mHSPC and nmCRPC patients treated with enzalutamide.
- In both trials, a proportion of enzalutamide-treated patients experienced rPD without PSA rise or progression, more commonly than in control groups.
- Patients with rPD, regardless of PSA changes, had worse overall survival compared to those without rPD.
- The study highlights discordance between imaging and PSA progression, recommending periodic imaging surveillance during enzalutamide treatment.